118316-12-4 Usage
Uses
Used in Pharmaceutical Industry:
(3α,5β,7β)-3,7-Dihydroxy-24norcholane-23-nitrile is used as an intermediate in the synthesis of ursodeoxycholic acid amides. These amides serve as glucocorticoid receptor modulators, which are important in the treatment of various inflammatory and immune disorders. The compound's unique structure allows for the development of targeted therapies with potential applications in the management of chronic diseases.
Used in Chemical Research:
As a white solid with distinct chemical properties, (3α,5β,7β)-3,7-Dihydroxy-24norcholane-23-nitrile can also be utilized in chemical research for the development of new compounds and materials. Its structural features make it a valuable starting point for the synthesis of novel steroidal derivatives with potential applications in various fields, including pharmaceuticals, agrochemicals, and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 118316-12-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,8,3,1 and 6 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 118316-12:
(8*1)+(7*1)+(6*8)+(5*3)+(4*1)+(3*6)+(2*1)+(1*2)=104
104 % 10 = 4
So 118316-12-4 is a valid CAS Registry Number.
118316-12-4Relevant articles and documents
OPTIMIZED SYNTHESIS OF PURE, NON-POLYMORPHIC, CRYSTALLINE BILE ACIDS WITH DEFINED PARTICLE SIZE
-
Page/Page column 15, (2012/06/16)
The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.
Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
-
Page/Page column 6-7, (2012/07/03)
The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.
